Benzinga | May 10, 2021 08:08AM EDT

Rubius Therapeutics Q1 EPS $(0.51) Beats $(0.52) Estimate

Rubius Therapeutics (NASDAQ:RUBY) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.52) by 1.92 percent. This is a 15 percent increase over losses of $(0.60) per share from the same period last year.